title: Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.
abstract: OBJECTIVE
  Contrast-induced nephropathy (CIN) remains a leading cause of iatrogenic acute renal failure. Terlipressin, a long-acting analog of vasopressin, may improve renal function. This study aimed to investigate the possible protective effect of terlipressin against the development of experimental CIN in rats.
  
  
  METHODS
  Wistar albino rats (n = 32) were allocated randomly into four equal groups of 8 each, i.e. control, terlipressin, contrast media (CM), and terlipressin plus contrast media (TCM). CIN was induced by intravenous administration of indomethacin (10 mg/kg), N-nitro L-arginine methyl ester (L-NAME, 10 mg/kg, twice at 15 and 30 min), and high-osmolar contrast media meglumine amidotrizoate 60%. Renal function parameters, kidney histology, and tubular expression of vascular endothelial growth factor (VEGF) were determined.
  
  
  RESULTS
  Mean serum creatinine levels were decreased (p < 0.05) and creatinine clearance (p < 0.05) increased in the TCM group compared with the CM group. Notably, rats in the TCM group displayed less tubular necrosis (p < 0.05), medullary congestion (p < 0.05), and a reduced tubular expression of VEGF (p < 0.05) compared with the CM group.
  
  
  CONCLUSIONS
  These results demonstrate that terlipressin can inhibit the development of CIN.
authors.affiliation: Department of Nephrology, Marmara University School of Medicine, Istanbul, Turkey.
authors.forename: Elif
authors.initials: E
authors.lastname: Ari
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Yilmaz
authors.forename: Alla Elden
authors.initials: AE
authors.lastname: Kedrah
authors.forename: Yesim
authors.initials: Y
authors.lastname: Alahdab
authors.forename: Fulya
authors.initials: F
authors.lastname: Cakalagaoglu
authors.forename: Hakki
authors.initials: H
authors.lastname: Arikan
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Kocak
authors.forename: Beyza
authors.initials: B
authors.lastname: Macunluoglu
authors.forename: Aydin
authors.initials: A
authors.lastname: Atakan
authors.forename: Arzu
authors.initials: A
authors.lastname: Kahveci
authors.forename: Ebru
authors.initials: E
authors.lastname: Asicioglu
authors.forename: Serhan
authors.initials: S
authors.lastname: Tuglular
authors.forename: Cetin
authors.initials: C
authors.lastname: Ozener
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000517:prevention & control; D000818:Animals; D003287:Contrast Media / Q000009:adverse effects*; D004195:Disease Models, Animal; D007677:Kidney Function Tests; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D011913:Rats, Inbred BB; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*; D014667:Vasopressins / Q000819:agonists*
chemical_list: D003287:Contrast Media; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D008236:Lypressin; D000077585:Terlipressin